Propranolol for management of Infantile Haemangioma: A Single Centre Experience
Keywords:
Propranolol, Hemangioma, Beta-Blocker
Abstract
Objective: Infantile hemangiomas are the most common benign tumour in infancy. Propranolol has recently been introduced as therapeutic agent for treating hemangiomas. This study explores the impact of Propranolol on hemangiomas.
Study Design: Prospective study.
Materials and Methods: Propranolol was given to 32 children (19 girls and 13 boys) having hemangiomas between age of 3 weeks to 12 months at a dose of 2 mg/kg per day, in 2 or 3 divided doses. Total duration of study period was one year from July 2013 to June 2014. Serial photographs were taken at 4-6 weeks interval during the course of their therapy to record clinical response.
Results: out of 32 patients 31 patients showed improvement in their hemangiomas by reduction in size and change in color during propranolol therapy. Results were determined as complete resolution (n- 5, 15.6%), ongoing resolution (n-26, 81.2%). No side effects of propranolol was observed in any patient.
Conclusions: Propranolol appears to be a valuable and effective treatment option for infantile hemangiomas. Propranolol is likely to revolutionize the treatment of hemangiomas.
Downloads
Download data is not yet available.
References
1. Frieden IJ, Haggstrom A, Drolet BA, et al. Infantile hemangiomas: current knowledge, future directions: proceedings of a research workshop on infantile hemangiomas. Pediatr Dermatol. 2005;22(5):383– 406.
2. Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics. 1998;101(3):446–452. [PubMed]
3. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006;118:882–887. [PubMed]
4. Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 2004;57:168–171. [PubMed]
5. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358: 2649–2651. [PubMed]
6. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009;119:2051–2054.
7. Theletsane T, Redfern A, Raynham O, Harris T, Prose NS, Khumalo NP. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009 Apr 9 [Epub ahead of print]. [PubMed]
8. Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G, Garabedian EN. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol2009;73:1168–1172. [PubMed]
9. The Laryngoscope VC 2010 The American Laryngological, Rhinological and Otological Society, Inc. Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center, Lisa M. Buckmiller, MD; Patrick D. Munson, MD; Umesh Dyamenahalli, MD; Yuemeng Dai, MD, PhD; Gresham T. Richter, MD.
10. Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987;18:103-5. [PubMed]
11. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291–294.
12. Mulliken JB, Glowacki J. Classification of pediatric vascular lesions. Plast Reconstr Surg1982;70:120–121. [PubMed]
13. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997;37:631-7. [PubMed]
14. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001;137:1208. [PubMed]
15. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001;27:475-85. [PubMed]
16. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999;104:1616-23.
17. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986;17:229-31. [PubMed]
18. Truong MT, Chang KW, Berk DR, et al. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010;156:335-8.
19. Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolargyngol 2010;74:338-42. [PubMed]
20. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infants [letter]. N Engl J Med 2008;359:2846. [PubMed]
21. Bonifazi E, Mazzotta F, Balduci G, et al. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol 2008;18:185-92.
22. Sans V, Dumas de la Roque E, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:e423-e431. [PubMed]
23. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009;26:610-4. [PubMed]
24. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. Laryngoscope.2010;120:676–81.
25. Qin ZP, Liu XJ, Li KL, Zhou Q, Yang XJ, Zheng JW. Treatment of infantile hemangiomas with low-dose propranolol: Evaluation of short-term efficacy and safety. Zhonghua Yi Xue Za Zhi. 2009;89:3130–4.
2. Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics. 1998;101(3):446–452. [PubMed]
3. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006;118:882–887. [PubMed]
4. Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 2004;57:168–171. [PubMed]
5. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358: 2649–2651. [PubMed]
6. Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009;119:2051–2054.
7. Theletsane T, Redfern A, Raynham O, Harris T, Prose NS, Khumalo NP. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009 Apr 9 [Epub ahead of print]. [PubMed]
8. Denoyelle F, Leboulanger N, Enjolras O, Harris R, Roger G, Garabedian EN. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol2009;73:1168–1172. [PubMed]
9. The Laryngoscope VC 2010 The American Laryngological, Rhinological and Otological Society, Inc. Propranolol for Infantile Hemangiomas: Early Experience at a Tertiary Vascular Anomalies Center, Lisa M. Buckmiller, MD; Patrick D. Munson, MD; Umesh Dyamenahalli, MD; Yuemeng Dai, MD, PhD; Gresham T. Richter, MD.
10. Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987;18:103-5. [PubMed]
11. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291–294.
12. Mulliken JB, Glowacki J. Classification of pediatric vascular lesions. Plast Reconstr Surg1982;70:120–121. [PubMed]
13. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997;37:631-7. [PubMed]
14. Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001;137:1208. [PubMed]
15. Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001;27:475-85. [PubMed]
16. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999;104:1616-23.
17. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986;17:229-31. [PubMed]
18. Truong MT, Chang KW, Berk DR, et al. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010;156:335-8.
19. Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolargyngol 2010;74:338-42. [PubMed]
20. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infants [letter]. N Engl J Med 2008;359:2846. [PubMed]
21. Bonifazi E, Mazzotta F, Balduci G, et al. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol 2008;18:185-92.
22. Sans V, Dumas de la Roque E, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009;124:e423-e431. [PubMed]
23. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009;26:610-4. [PubMed]
24. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Y, Richter GT. Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center. Laryngoscope.2010;120:676–81.
25. Qin ZP, Liu XJ, Li KL, Zhou Q, Yang XJ, Zheng JW. Treatment of infantile hemangiomas with low-dose propranolol: Evaluation of short-term efficacy and safety. Zhonghua Yi Xue Za Zhi. 2009;89:3130–4.
CITATION
DOI: 10.17511/ijmrr.2015.i1.25
Published: 2015-02-28
How to Cite
1.
Singh N, Rohit D, Singh S, Thakur O, Verma RS. Propranolol for management of Infantile Haemangioma: A Single Centre Experience. Int J Med Res Rev [Internet]. 2015Feb.28 [cited 2024Nov.8];3(1):40-4. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/183
Section
Original Article
OAI - Open Archives Initiative
